Emerging Multiplex Nucleic Acid Diagnostic Tests for Combating COVID-19

Biosensors (Basel). 2022 Nov 7;12(11):978. doi: 10.3390/bios12110978.

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 has drawn attention to the need for fast and accurate diagnostic testing. Concerns from emerging SARS-CoV-2 variants and other circulating respiratory viral pathogens further underscore the importance of expanding diagnostic testing to multiplex detection, as single-plex diagnostic testing may fail to detect emerging variants and other viruses, while sequencing can be too slow and too expensive as a diagnostic tool. As a result, there have been significant advances in multiplex nucleic-acid-based virus diagnostic testing, creating a need for a timely review. This review first introduces frequent nucleic acid targets for multiplex virus diagnostic tests, then proceeds to a comprehensive and up-to-date overview of multiplex assays that incorporate various detection reactions and readout modalities. The performances, advantages, and disadvantages of these assays are discussed, followed by highlights of platforms that are amenable for point-of-care use. Finally, this review points out the remaining technical challenges and shares perspectives on future research and development. By examining the state of the art and synthesizing existing development in multiplex nucleic acid diagnostic tests, this review can provide a useful resource for facilitating future research and ultimately combating COVID-19.

Keywords: COVID-19; SARS-CoV-2; multiplex; nucleic acid amplification testing; point-of-care; virus.

Publication types

  • Review

MeSH terms

  • COVID-19* / diagnosis
  • Diagnostic Tests, Routine
  • Humans
  • Nucleic Acid Amplification Techniques
  • Nucleic Acids*
  • Pandemics
  • SARS-CoV-2
  • Sensitivity and Specificity

Substances

  • Nucleic Acids

Supplementary concepts

  • SARS-CoV-2 variants